Tags » Daiichi Sankyo

CS 3150, angiotensin II receptor antagonist, for the treatment or prevention of such hypertension and heart disease

CS-3150,  (XL550)

CS 3150, angiotensin II receptor antagonist,  for the treatment or prevention of such hypertension and heart disease similar to olmesartan , losartan, candesartan , valsartan,  irbesartan,  telmisartan, eprosartan, 5,060 more words

Daiichi Sankyo receives FDA approval for anti-clotting drug Savaysa , EDOXABAN

Edoxaban, DU-176b

Daiichi Sankyo receives FDA approval for anti-clotting drug Savaysa
Japanese drug-maker Daiichi Sankyo has obtained approval from US Food and Drug Administration (FDA) for its anti-clotting drug Savaysa (edoxaban tablets)..8 JAN 2015… 3,221 more words

FDA 2015

FDA Advisory Panel Gives Tepid Support To New Daiichi Sankyo Drug

On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo’s edoxaban(Savaysa), but the outcome will likely result in a drug that will be on the market but that few physicians will prescribe until further studies are performed. 9 more words

Policy & Ethics

Billionaire Dilip Shanghvi Inks $4 Billion Deal With Daiichi Sankyo To Buy Rival Ranbaxy

Sun Pharmaceutical Industries makes mega acquisition to forge its position as world’s 5th largest generics firm